MAPS Responds to FDA Continue Clinical Hold with Protocol A3V1, Agreed to All

On September 15, 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continued clinical hold with Protocol A3V1 and agreed to all.